Host factors		HIV-1 genes
ADCY1*	adenylate cyclase 1	env, tat, nef
AKT3	v-akt murine thymoma viral oncogene homolog 3	env, tat
ATM	ataxia telangiectasia mutated	pol, rev
CBX5	chromobox homolog 5	vpr
CCR5*	chemokine (C-C motif) receptor 5	env
CEBPB	CCAAT/enhancer binding protein	tat
EP300	E1A binding protein p300	tat, vpr
PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha	env, tat
PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	env, tat
PIK3R1*	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	nef, tat
POU2F1	POU class 2 homeobox 1	tat
PRKAR2A*	protein kinase, cAMP-dependent, regula- tory, type II, alpha	gag, vpr, nef
PRKAR2B*	protein kinase, cAMP-dependent, regula- tory, type II, beta	gag, vpr, nef
PRKD1	protein kinase D1	tat
PTPRC	protein tyrosine phosphatase, receptor type, C	env
REL*	v-rel reticuloendotheliosis viral oncogene homolog	tat
SP1	Sp1 transcription factor	tat, vpr
SP3	Sp3 transcription factor	tat

*, asterisk represents host factor identified in both 0.004% and 0.04% CSC

Table1:HIV-1 associated host factors after 0.004% CSC treatment.

Host factors		HIV-1 genes
ADCY1*	adenylate cyclase 1	env, tat, nef
BCL2	B-cell CLL/lymphoma 2	pol
CCNT1	cyclin T1	gag, tat
CCR5*	chemokine (C-C motif) receptor 5	env
ICAM1	intercellular adhesion molecule 1	env, gag
ITGB3	integrin, beta 3	tat
MME	membrane metallo-endopeptidase	tat
NCOA3	nuclear receptor coactivator 3	tat
NFATC2	nuclear factor of activated T-cells, cytoplas- mic, calcineurin-dependent 2	tat
PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	nef, tat
PIK3R1*	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	nef, tat
PRKACB	protein kinase, cAMP-dependent, catalytic, beta	gag, vpr, nef
PRKAR2A*	protein kinase, cAMP-dependent, regula- tory, type II, alpha	gag, vpr, nef
PRKAR2B*	protein kinase, cAMP-dependent, regula- tory, type II, beta	gag, vpr, nef
PRKDC	protein kinase, DNA-activated, catalytic polypeptide	vpu
REL*	v-rel reticuloendotheliosis viral oncogene homolog	tat
RPA4	replication protein A4	pol
SDC2	syndecan 2	env, tat, gag
SDC4	syndecan 4	env, tat, gag
SERPINA1	serpin peptidase inhibitor, clade A	env, gag
TCERG1	transcription elongation regulator 1	tat
TGM2	transglutaminase 2	env, rev

*, asterisk represents host factor identified in both 0.004% and 0.04% CSC treatments.

Table2: HIV-1 associated host factors after 0.04% CSC treatment.

Figure 1: The effects of CSC treatment on HIV-1 replication in PBMCs. Fold change in viral replication was calculated by comparing the replication efficiency of HIV-1 in CSC-treatment groups to that of DMSO-treated cells. Mean fold change is depicted with standard deviation. *, p < 0.05, Student’s t test (n=2)

Figure 2: Network analysis of HIV-1 associated host factors modulated by 0.04% CSC treatment. Nineteen of the 22 host factors (grey oval) in Table 2 belong to a highly scored network. Among the host factors, CCR5, PRKDC and RPA4 are not present in this network. Key cellular proteins (white circle) related to the host factors are shown.

Figure 3: Network analysis of HIV-1 associated host factors modulated by 0.004% CSC treatment. Seventeen of the 18 host factors (grey oval) in Table 1 belong to a highly scored network. Among the host factors, CBX5 is not present in this network. Key cellular proteins (white circle) related to the host factors are shown.